Compare Adaptive Biotechnologies Corp (ADPT) vs NextEra Energy, Inc. (NEE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs NextEra Energy, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $20.05 (market cap $3.33B), while NextEra Energy, Inc. trades at $87.62 (market cap $184.51B). The key difference: NextEra Energy, Inc. is far larger — about 55.4× Adaptive Biotechnologies Corp's market cap, and NextEra Energy, Inc. pays a 2.82% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | NEE | |
|---|---|---|
Market Cap | $3.33B | $184.51B |
Sector | Health | Utilities |
52-Week High | $22.37 | $97.88 |
52-Week Low | $10.24 | $69.77 |
Enterprise Value | $3.19B | $286.92B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
NextEra Energy (NEE) trades at $88.47, up 0.15% today, with a neutral technical outlook and strong analyst support. The stock shows solid fundamentals with a P/E of 22.19, net income margin of 29.37%, and recent earnings beats in Q1 2026. Revenue grew to $27.41B in 2025, though net income dipped slightly to $6.84B. A recent $0.62 dividend underscores shareholder returns, while the Dominion Energy merger positions NEE for AI-driven power demand growth.
Outlook remains positive with a consensus price target of $104.29 (18% upside), driven by clean energy demand and partnerships. Risks include rising debt-to-asset ratios (47.6% in 2025) and regulatory pressures. Institutional sentiment is bullish with 66.7% buy ratings, but investors should monitor execution on capital expenditures and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →
